| MeSH term | MeSH ID | Detail |
|---|---|---|
| Atherosclerosis | D050197 | 85 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Arteriosclerosis | D001161 | 86 associated lipids |
| Diabetes Mellitus, Type 2 | D003924 | 87 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Diabetes Mellitus | D003920 | 90 associated lipids |
| Hypercholesterolemia | D006937 | 91 associated lipids |
| Insulin Resistance | D007333 | 99 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Khosla S | Magic bullets to kill nasty osteoclasts. | 2005 | Endocrinology | pmid:16009971 |
| Feng X | RANKing intracellular signaling in osteoclasts. | 2005 | IUBMB Life | pmid:16012047 |
| Stenman UH et al. | Prognostic value of serum markers for prostate cancer. | 2005 | Scand J Urol Nephrol Suppl | pmid:16019759 |
| Li J et al. | [Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro]. | 2005 | Di Yi Jun Yi Da Xue Xue Bao | pmid:16027068 |
| Pipes GD et al. | Optimization and applications of CDAP labeling for the assignment of cysteines. | 2005 | Pharm. Res. | pmid:16028006 |
| Yang S et al. | Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. | 2005 | J. Immunol. | pmid:16034140 |
| Deschner J et al. | Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus. | 2006 | J Biomech | pmid:16038916 |
| Guang-da X et al. | Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16046585 |
| Kazama JJ et al. | Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. | 2005 | Clin. Nephrol. | pmid:16047647 |
| Zahanich I et al. | Molecular and functional expression of voltage-operated calcium channels during osteogenic differentiation of human mesenchymal stem cells. | 2005 | J. Bone Miner. Res. | pmid:16059635 |
| Cao JJ et al. | Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse. | 2005 | J. Bone Miner. Res. | pmid:16059637 |
| Terpos E et al. | The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. | 2005 | Leukemia | pmid:16079895 |
| Huang P et al. | [In vitro study of combination rhOPG-Fc and alendronate on inhibition osteoclast]. | 2005 | Zhonghua Wai Ke Za Zhi | pmid:16083587 |
| Kwon OH et al. | The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16083856 |
| Hayton MJ et al. | Involvement of adenosine 5'-triphosphate in ultrasound-induced fracture repair. | 2005 | Ultrasound Med Biol | pmid:16085103 |
| von Knoch F et al. | Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. | 2005 | J Biomed Mater Res A | pmid:16088891 |
| Ashcroft AJ and Carding SR | RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation. | 2005 | Gut | pmid:16099805 |
| Zojer N et al. | Bisphosphonate treatment does not affect serum levels of osteoprotegerin and RANKL in hypercalcemic cancer patients. | 2005 Sep-Oct | Anticancer Res. | pmid:16101188 |
| Lems WF and Bijlsma JW | [Clinical implications of new insights into the regulation of bone resorption]. | 2005 | Ned Tijdschr Geneeskd | pmid:16104110 |
| Daroszewska A and Ralston SH | Genetics of Paget's disease of bone. | 2005 | Clin. Sci. | pmid:16104845 |
| Rogers A and Eastell R | Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. | 2005 | J. Clin. Endocrinol. Metab. | pmid:16105967 |
| Wise GE et al. | CSF-1 regulation of osteoclastogenesis for tooth eruption. | 2005 | J. Dent. Res. | pmid:16109994 |
| Yang KC et al. | [Effect of nylestriol and levonorgestrel on the expression of Opg/OPGL in human osteosarcoma MG-63 cell lines]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16114553 |
| Ziegler S et al. | Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. | 2005 | Atherosclerosis | pmid:16115489 |
| Gonnelli S et al. | Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. | 2005 | J. Endocrinol. Invest. | pmid:16117195 |
| Zhou Z et al. | Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. | 2005 | Cancer | pmid:16121404 |
| Avignon A et al. | Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. | 2005 | Diabetes Care | pmid:16123486 |
| Kusumi A et al. | Regulation of synthesis of osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand in normal human osteoblasts via the p38 mitogen-activated protein kinase pathway by the application of cyclic tensile strain. | 2005 | J. Bone Miner. Metab. | pmid:16133687 |
| Deftos LJ | Treatment of Paget's disease--taming the wild osteoclast. | 2005 | N. Engl. J. Med. | pmid:16135831 |
| Cundy T et al. | Recombinant osteoprotegerin for juvenile Paget's disease. | 2005 | N. Engl. J. Med. | pmid:16135836 |
| Su X et al. | [Effects of parathyroid hormone on osteoprotegerin expression and osteoprotegerin ligand and their related cytokines in human osteoblasts]. | 2004 | Zhong Nan Da Xue Xue Bao Yi Xue Ban | pmid:16137047 |
| Heinrich J et al. | CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption. | 2005 | Arch. Oral Biol. | pmid:16137499 |
| Moschen AR et al. | The RANKL/OPG system and bone mineral density in patients with chronic liver disease. | 2005 | J. Hepatol. | pmid:16143421 |
| Yang YQ et al. | Human periodontal ligament cells express osteoblastic phenotypes under intermittent force loading in vitro. | 2006 | Front. Biosci. | pmid:16146769 |
| Takahashi N et al. | [Osteoprotegerin (OPG)]. | 2005 | Nippon Rinsho | pmid:16149650 |
| Choi JY et al. | Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. | 2005 | Calcif. Tissue Int. | pmid:16151677 |
| Viereck V et al. | Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. | 2005 | J. Cell. Biochem. | pmid:16152630 |
| Crisafulli A et al. | Osteoprotegerin and bone mineral density in hemodiafiltration patients. | 2005 | Ren Fail | pmid:16152990 |
| Lau YS et al. | Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. | 2005 | Hum. Pathol. | pmid:16153456 |
| Zhou YQ et al. | [OPG and OPGL expression in condyle cartilage of temporomandibular joint following anterior disc displacement]. | 2005 | Shanghai Kou Qiang Yi Xue | pmid:16155701 |
| Holen I et al. | Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? | 2005 | Breast Cancer Res. Treat. | pmid:16155791 |
| Hong JS et al. | Maternal plasma osteoprotegerin concentration in normal pregnancy. | 2005 | Am. J. Obstet. Gynecol. | pmid:16157103 |
| Raustyte G et al. | Calcium deposition and expression of bone modelling markers in the tympanic membrane following acute otitis media. | 2006 | Int. J. Pediatr. Otorhinolaryngol. | pmid:16159670 |
| Stolina M et al. | RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. | 2005 | J. Bone Miner. Res. | pmid:16160733 |
| Yasuda H | [OPG, anti-rANKL antibody]. | 2005 | Nippon Rinsho | pmid:16164225 |
| Ueland T and Bollerslev J | Bone metabolism and growth hormone deficiency. Experimental and clinical aspects. | 2005 | Front Horm Res | pmid:16166760 |
| Ulrich-Vinther M et al. | Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties. | 2005 | Bone | pmid:16169783 |
| Hjertner Ø et al. | Identification of new targets for therapy of osteolytic bone disease in multiple myeloma. | 2005 | Curr Drug Targets | pmid:16178802 |
| Nardelli B et al. | Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells. | 2006 | Endocrinology | pmid:16179414 |
| Kostenuik PJ | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. | 2005 | Curr Opin Pharmacol | pmid:16188502 |
| Sakakura Y et al. | Immunolocalization of receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG) in Meckel's cartilage compared with developing endochondral bones in mice. | 2005 | J. Anat. | pmid:16191162 |
| Meng XM et al. | [Expression of receptor activator of NF-kappa B ligand and osteoprotegerin protein in the giant cell lesions of jaw]. | 2005 | Zhonghua Kou Qiang Yi Xue Za Zhi | pmid:16191370 |
| Tabuchi M et al. | Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. | 2005 | Calcif. Tissue Int. | pmid:16193235 |
| Otsuka T et al. | Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. | 2005 | J Dent | pmid:16199283 |
| Neumann E et al. | The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: new insights from animal models. | 2005 | Arthritis Rheum. | pmid:16200575 |
| Liu D et al. | Chronology and regulation of gene expression of RANKL in the rat dental follicle. | 2005 | Eur. J. Oral Sci. | pmid:16202028 |
| Xie F et al. | Increase in bone mass and bone strength by Sambucus williamsii HANCE in ovariectomized rats. | 2005 | Biol. Pharm. Bull. | pmid:16204939 |
| Juarranz Y et al. | Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. | 2005 | Arthritis Res. Ther. | pmid:16207319 |
| Görtz B et al. | Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. | 2005 | Arthritis Res. Ther. | pmid:16207331 |
| Pantsulaia I et al. | Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. | 2005 | Cytokine | pmid:16213155 |
| Low E et al. | Expression of mRNA for osteoprotegerin and receptor activator of nuclear factor kappa beta ligand (RANKL) during root resorption induced by the application of heavy orthodontic forces on rat molars. | 2005 | Am J Orthod Dentofacial Orthop | pmid:16214633 |
| Schneeweis LA et al. | Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. | 2005 | J. Biol. Chem. | pmid:16215261 |
| Bezerra MC et al. | Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. | 2005 | Rheumatology (Oxford) | pmid:16219645 |
| Minenna G et al. | [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report]. | 2005 | Recenti Prog Med | pmid:16229324 |
| Zwerina J et al. | Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. | 2005 | FASEB J. | pmid:16234431 |
| Viereck V et al. | Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts. | 2005 | J. Bone Miner. Res. | pmid:16234977 |
| Gajewska J et al. | [The impairement of bone formation and resorption in 25-year-old man with neglected celiac disease]. | 2005 | Wiad. Lek. | pmid:16238129 |
| Ruocco MG and Karin M | IKK{beta} as a target for treatment of inflammation induced bone loss. | 2005 | Ann. Rheum. Dis. | pmid:16239395 |
| Anandarajah AP and Schwarz EM | Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications. | 2006 | J. Cell. Biochem. | pmid:16240334 |
| Palma MA and Body JJ | Usefulness of bone formation markers in breast cancer. | 2005 Jul-Sep | Int. J. Biol. Markers | pmid:16240842 |
| Hsu YH et al. | Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. | 2006 | Hum. Genet. | pmid:16249885 |
| Palmqvist P et al. | Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway. | 2006 | J. Biol. Chem. | pmid:16251181 |
| Xiao HL et al. | [Expression and activity determination of TNFR domain of osteoprotegerin in E.coli and corresponding antibody preparation]. | 2005 | Yi Chuan | pmid:16257908 |
| Liu W et al. | Receptor activator of NF-kappaB (RANK) cytoplasmic motif, 369PFQEP373, plays a predominant role in osteoclast survival in part by activating Akt/PKB and its downstream effector AFX/FOXO4. | 2005 | J. Biol. Chem. | pmid:16260781 |
| Yeung RS | Bones, blood vessels, and the immune system: what's the link? | 2005 | J. Rheumatol. | pmid:16265680 |
| Simonini G et al. | Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. | 2005 | J. Rheumatol. | pmid:16265708 |
| Tanaka H et al. | Nicotine and lipopolysaccharide stimulate the formation of osteoclast-like cells by increasing macrophage colony-stimulating factor and prostaglandin E2 production by osteoblasts. | 2006 | Life Sci. | pmid:16266722 |
| Kim SM et al. | Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. | 2005 | Clin. Endocrinol. (Oxf) | pmid:16268814 |
| Secchiero P et al. | Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. | 2006 | J. Cell. Physiol. | pmid:16270354 |
| Tarquini R et al. | Circasemidian rather than circadian variation of circulating osteoprotegerin in clinical health. | 2005 | Biomed. Pharmacother. | pmid:16275499 |
| Cozzani M et al. | Transcription Factor Decoy (TFD) as a novel approach for the control of osteoclastic resorption. | 2005 | Prog Orthod | pmid:16276433 |
| Gaudio A et al. | Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? | 2005 | J. Endocrinol. Invest. | pmid:16277162 |
| Taubman MA et al. | Immune response: the key to bone resorption in periodontal disease. | 2005 | J. Periodontol. | pmid:16277573 |
| Bartold PM et al. | Periodontitis and rheumatoid arthritis: a review. | 2005 | J. Periodontol. | pmid:16277578 |
| Kaji H et al. | Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. | 2005 | Horm. Metab. Res. | pmid:16278780 |
| Morena M et al. | Plasma osteoprotegerin is associated with mortality in hemodialysis patients. | 2006 | J. Am. Soc. Nephrol. | pmid:16280472 |
| Kishimoto K et al. | Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. | 2006 | Histochem. Cell Biol. | pmid:16283360 |
| Wise GE et al. | Injections of osteoprotegerin and PMA delay tooth eruption. | 2006 | Clin Anat | pmid:16283633 |
| Cross SS et al. | Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? | 2006 | Int. J. Cancer | pmid:16287088 |
| Schoppet M et al. | TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16288714 |
| Michael H et al. | Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. | 2005 | J. Bone Miner. Res. | pmid:16294275 |
| Nicholls BM et al. | Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor. | 2005 | J. Bone Miner. Res. | pmid:16294279 |
| Andelković Z et al. | [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent]. | 2005 Jul-Aug | Med. Pregl. | pmid:16296579 |
| Hormdee D et al. | Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts. | 2005 | Clin. Exp. Immunol. | pmid:16297161 |
| Humphrey EL et al. | Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. | 2006 | Bone | pmid:16298558 |
| Geusens P and Reid D | Newer drug treatments: their effects on fracture prevention. | 2005 | Best Pract Res Clin Rheumatol | pmid:16301192 |
| Hamdy NA | Osteoprotegerin as a potential therapy for osteoporosis. | 2005 | Curr Osteoporos Rep | pmid:16303111 |
| Wiercinska-Drapalo A et al. | Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. | 2005 | Prostaglandins Other Lipid Mediat. | pmid:16303613 |
| Yang M et al. | Chemokine and chemokine receptor expression during colony stimulating factor-1-induced osteoclast differentiation in the toothless osteopetrotic rat: a key role for CCL9 (MIP-1gamma) in osteoclastogenesis in vivo and in vitro. | 2006 | Blood | pmid:16304045 |
| Pettersen I et al. | Osteoprotegerin is expressed in colon carcinoma cells. | 2005 Nov-Dec | Anticancer Res. | pmid:16309167 |